30 January 2015 - US-based injectable drug delivery systems developer Unilife Corp. (NASDAQ: UNIS) (ASX: UNS) has priced an underwritten public offering in the United States of 11m shares of its common stock to the public at a price of USD 3.75 per share, the company said on Friday.

Unilife expects to see net proceeds from the offering of USD 38,792,500, after deducting underwriting discounts and commissions and estimated offering expenses payable by Unilife.

In addition, Unilife has granted the underwriters an option for a period of 30 days to purchase up to an additional 1.65m shares of its common stock.

The offering is expected to close on 4 February 4 subject to customary closing conditions.

Jefferies LLC and Piper Jaffray and Co. are acting as joint book-running managers for the offering. Griffin Securities, Inc. is acting as a co-manager for the offering.

Unilife saidi texpects to use the net proceeds of the offering for investments in Unilife's plant, equipment, systems and personnel to further develop its manufacturing and operational capabilities to satisfy current and future customer orders and general corporate purposes, including working capital, acquisitions and other business opportunities.

The company's portfolio of products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems.